Related Experiment Video
Updated: May 11, 2026
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
Potential therapies for anaplastic lymphoma kinase-driven tumors in children: progress to date
1Division of Pediatric Hematology-Oncology, Children's Hospital of the King's Daughters, Norfolk, VA, USA.
Abstract:
Anaplastic lymphoma kinase (ALK) is an oncogenic tyrosine kinase that is deregulated due to a variety of molecular mechanisms in pediatric cancer. They include chromosomal translocations, activation mutations, and gene amplifications. Since the initial discovery of ALK as an oncogenic tyrosine kinase involved in the chromosomal translocation t(2, 5)(p23;q35) in 1994, more than 20 translocation partners of ALK have been identified in various cancers. Furthermore, deregulation of ALK tyrosine kinase activity is critical for the pathogenesis of several other pediatric tumors, including neuroblastomas and inflammatory myofibroblastic tumors. The recent discovery of ALK translocations in adult lung cancer patients (non-small cell lung cancer) has accelerated the development of inhibitors of ALK tyrosine kinase as therapeutic agents. While excellent clinical response has been observed in many patients, the acquisition of clinical resistance to ALK inhibition highlights the need for development of second-generation ALK kinase inhibitors and/or combination therapies that target downstream signaling mediators or antibody drug conjugates. This article provides an update on the spectrum of ALK-driven tumors in the pediatric population and the potential therapies which target these tumors.
Insights
Anaplastic lymphoma kinase (ALK) drives pediatric cancers through genetic changes. New therapies are needed as resistance to current ALK inhibitors emerges.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Anaplastic lymphoma kinase (ALK) is a key oncogenic tyrosine kinase implicated in various pediatric cancers.
- ALK deregulation occurs through chromosomal translocations, mutations, and amplifications, driving tumor development.
- Over 20 ALK translocation partners have been identified since its 1994 discovery.
Purpose of the Study:
- To provide an updated overview of ALK-driven tumors within the pediatric population.
- To discuss the current and potential therapeutic strategies targeting these pediatric ALK-driven tumors.
Main Methods:
- Literature review and synthesis of existing research on ALK in pediatric oncology.
- Analysis of molecular mechanisms leading to ALK deregulation.
- Evaluation of current and emerging therapeutic approaches.
Main Results:
- ALK plays a critical role in the pathogenesis of neuroblastomas and inflammatory myofibroblastic tumors.
- ALK translocations are also found in adult non-small cell lung cancer, spurring inhibitor development.
- Clinical resistance to ALK inhibitors necessitates the development of next-generation treatments.
Conclusions:
- Targeting ALK is a crucial strategy for treating specific pediatric cancers.
- Further research into second-generation inhibitors and combination therapies is essential to overcome resistance.
- Understanding the spectrum of ALK-driven tumors is key to advancing pediatric cancer treatment.
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
